Aethlon Medical Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.21 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $6.52Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $4.6M Enterprise Value −$389.9K Shares Outstanding 711.1K diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Aethlon Medical is a clinical-stage medical technology company focused on its proprietary Hemopurifier platform, which targets the depletion of cancer-promoting extracellular vesicles (EVs) and life-threatening circulating viruses. While the company has successfully advanced its Australian oncology safety trial into its third and final cohort with no reported dose-limiting toxicities, it remains a pre-revenue entity with a persistent going-concern risk. The company's cash position of approximately $5.0 million as of March 31, 2026, supplemented by subsequent ATM sales, provides limited runway, making strategic partnerships or dilutive equity financings highly likely. Consequently, a Hold recommendation is warranted until clinical efficacy data is established and the balance sheet is stabilized. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$1.50 Mean target$3.25 High · most bullish analyst$5.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company experiences safety issues or lack of clear biomarker efficacy in Cohort 3, delaying regulatory submissions. Furthermore, inability to raise sufficient capital under the ATM program or through strategic partnerships leads to severe liquidity constraints, triggering a going-concern failure or delisting from the Nasdaq Capital Market. Base CaseCentral scenario The company successfully completes Cohort 3 of its Australian oncology trial during the summer of 2026, demonstrating a strong safety profile with no serious adverse events. Regulatory submissions are made to the Australian TGA and the US FDA later in 2026. The company continues to fund operations through its ATM program and minor equity placements, maintaining its Nasdaq listing but causing moderate dilution to existing shareholders. Bull CaseUpside scenario The Hemopurifier platform has demonstrated significant preclinical and early clinical safety/feasibility in removing disease-promoting extracellular vesicles (EVs) and viruses. Successful progression to Cohort 3 of the Australian oncology study brings the company closer to generating key clinical data that could validate the platform, attract strategic pharmaceutical partnerships, and open up large addressable markets in oncology, infectious diseases, and organ transplantation. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |